Background: Bevacizumab is an antiangiogenic mAb with efficacy against several cancers, but it is associated with risk of arterial thromboembolism (ATE). Further data are needed to determine the safety of bevacizumab.
introduction
Bevacizumab is a humanised mAb directed against the vascular endothelial growth factor (VEGF). In the pivotal phase III trial in metastatic colorectal cancer (mCRC) by Hurwitz et al. [1] , the addition of bevacizumab to irinotecan-based combination chemotherapy improved progression-free survival and overall survival. Bevacizumab has clinical benefit in mCRC in combination with other chemotherapy regimens as first-line treatment and in combination with oxaliplatin-based chemotherapy in the second-line setting [2] [3] [4] [5] [6] . Furthermore, adding bevacizumab to chemotherapy has also improved outcomes in advanced non-small-cell lung cancer, breast cancer, and ovarian cancer [7] [8] [9] [10] .
Although bevacizumab is generally well tolerated, it may be associated with rare symptomatic toxic effects such as arterial thrombosis, delayed wound healing, bleeding, and gastrointestinal perforation. For elderly patients, many of whom have preexisting cardiovascular risk factors or known cardiovascular disease, particular concern surrounds the use of bevacizumab and the risk of arterial thromboembolism (ATE).
A post hoc analysis of five randomised controlled trials of bevacizumab with chemotherapy versus chemotherapy alone in patients with metastatic colorectal, breast, and non-small-cell lung carcinoma showed that the addition of bevacizumab increased the risk of ATE [hazard ratio 2.0, 95% confidence interval (CI) 1.05-3.75; P = 0.03] [11] . Increased risk of ATE was associated with age ‡65 years and a prior history of thromboembolism. Nearly 18% of patients aged ‡65 years with a history of prior ATE experienced ATE while receiving bevacizumab, compared with 2.2% of controls.
This report aims to further evaluate the safety of bevacizumab in terms of rates of ATE in the Australasian Gastro-Intestinal Trials Group's MAX (Mitomycin, Avastin, Xeloda) study, a previously reported randomised trial that evaluated the role of capecitabine, bevacizumab, and mitomycin C in the first-line setting for patients with mCRC [6] . This trial enrolled a somewhat older patient group (median age 67 years) than is usual in trials of combination chemotherapy in advanced colorectal cancer (CRC) and it included a detailed prospective cardiovascular risk factor assessment at baseline.
patients and methods

study design
The MAX study was an international randomised phase III trial for patients with mCRC. Patients were aged ‡18 years with a confirmed diagnosis of unresectable mCRC and no prior chemotherapy, other than adjuvant therapy. Other eligibility criteria included adequate bone marrow, renal and hepatic function; a life expectancy of at least 12 weeks; and Eastern Cooperative Oncology Group performance status of zero to two.
Patients considered to be at substantial risk of a vascular event (ATE within the preceding 12 months) were ineligible for participation in the study. However, patients with preexisting vascular disease who had had ATEs >12 months previously and patients with risk factors for ATE (hypertension, diabetes, hypercholesterolaemia, current smokers) were eligible for participation.
After written informed consent, patients were randomly allocated to one of the three treatment arms: capecitabine alone, capecitabine plus bevacizumab, capecitabine plus bevacizumab plus mitomycin C.
Treatment was continued until disease progression except for mitomycin C, which was limited to four cycles because of potential risk of haemolytic uraemic syndrome.
risk factor analysis and adverse events A pre-specified statistical analysis plan was generated before any data analysis was undertaken. Detailed data were collected prospectively on the trial case report forms. Data collected included age, aspirin use (at baseline and during the study), hypertension, hypercholesterolaemia, diabetes, smoking history, and previous ATE (angina pectoris, myocardial infarction, transient ischaemic attack, cerebrovascular accident, or peripheral vascular disease). Electrocardiography was carried out at baseline, and blood pressure measurements were taken at baseline and at least three weekly.
All toxic effects were reported as adverse events. The severity of each event was assessed according to the definitions and grades of the National Cancer Institute-Common Terminology Criteria for Adverse Events version 3.0. Data regarding grade 3, 4, and 5 ATE events were collected with ATE defined as cardiac ischaemia, cerebrovascular ischaemia, peripheral arterial ischaemia, and arterial thrombosis. For this analysis, events in the bevacizumab-containing arms (arms B and C) were pooled.
The study was conducted in accordance with the National Health and Medical Research Council 'National Statement on Ethical Conduct in Research Involving Humans' (1999) and was approved by the ethics committee at each participating institution. Table 1 .
Cardiovascular risk factors and the extent of preexisting vascular disease were comparable between the treatment arms. At study entry, 18% of patients were using aspirin. The median duration of treatment was 6 months in the capecitabine arm and 6.75 months in the two combination-treatment arms.
ATE events
There was a significant difference in the rates of ATE in patients receiving bevacizumab than in those receiving chemotherapy alone. No grade 3, 4, or 5 ATE occurred in patients receiving chemotherapy without bevacizumab, but 12 patients receiving bevacizumab (3.8%) experienced a grade 3, 4, or 5 ATE event (P = 0.01); 8 (2.5%) had cardiac ischaemia (myocardial infarction or angina) (P = 0.04) and 4 (1.3%) had a stroke or transient ischaemic attack (P = 0.20). There were no ATEs involving the peripheral arterial vasculature. Based on these data, the number of patients needed to be treated with bevacizumab in order to cause a grade 3, 4, or 5 ATE is 27 (95% CI 16-73).
Baseline risk factors for an event in the bevacizumab groups are shown in Table 2 . For patients over the age of 65 years, the rate of ATE was 2.1% compared with 6.3% for patients <65 years (P = 0.06). The rate among patients with a previous history of ATE was 5.0% compared with 3.7% for patients with no history of ATE (P = 0.72). The rate among patients with cardiac risk factors was 5.0% compared with 1.8% in patients without cardiac risk factors (P = 0.16). The rate in non-aspirin users was 2.7% and was 8.9% in patients using aspirin. However, this was a non-randomised comparison, and the aspirin-using group had higher proportions with cardiac risk factors (75% versus 61%) or a previous history of ATE (43% versus 6%). 
discussion
This detailed analysis of vascular toxicity in patients receiving bevacizumab confirms previous data, indicating that bevacizumab is associated with a modest increase in risk of ATE, with most of these events being cardiac. The overall rate of grade 3, 4, and 5 ATEs was 3.8% in the MAX study and is consistent with that reported by Scappaticci et al. [11] in his pooled analysis of bevacizumab in metastatic cancer of 3.8% (compared with 1.7% in controls). Although older age was not mandated as an inclusion criterion for the MAX study, the median age of patients was 67 years, which is older than the typical median age of 59 years in most studies in CRC with bevacizumab. In our study, 280 patients were over the age of 65 years, providing us with reasonable power to examine the effect of age on ATE risk. Scappaticci et al. reported an association between the occurrence of ATE and age >65 years and prior history of ATE on both univariate and multivariate analysis. The rates of grade 3/4 ATE in patients receiving bevacizumab were reported at 7.1% in patients >65 years, whereas in contrast in our study the rates of ATE were 2.1% in the same age group. The rates of ATE were also higher for patients with a prior history of ATE (15.7%) compared with 5% in our study. We also prospectively collected data on patients with cardiovascular risk factors and the incidence of ATE in bevacizumab-treated patients with cardiac risk factors was 5%, not significantly different from the rate in bevacizumab-treated patients without risk factors. The use of bevacizumab with chemotherapy in patients over the age of 65 years was also analysed by Kabbinavar et al. [12] in a pooled subgroup analysis of two placebo-controlled trials of first-line therapy in mCRC. In this retrospective study of 439 patients with a median age of 72 years, chemotherapy plus bevacizumab compared with chemotherapy and placebo improved progression-free survival (9.2 versus 6.2 months, respectively) and overall survival (19.3 versus 14.3 months) . The rate of ATE was 7.6% in the bevacizumab group and 2.8% in the placebo group; however, this study included ATE events of any grade. Cardiovascular events requiring discontinuation from the study were similar between the two groups suggesting that clinically significant adverse events occurred at a similar rate.
Further safety data have emerged from the BRiTE registry, a cohort study including patients treated with bevacizumab for mCRC, which explored continuation of bevacizumab beyond disease progression in a subgroup of 642 patients [13, 14] . Serious ATE occurred at a rate of 1.8% of 1953 assessable patients, among whom 45.9% of patients were aged >65 years. While longer exposure to bevacizumab was associated with an increased rate of hypertension, there did not appear to be any cumulative risk of ATE within the limits of these nonrandomised data.
Collectively, our data and other published data do not support age being a major risk factor for ATE in patients receiving bevacizumab. A prior history of ATE and/or cardiac risk factors may confer a small increased risk of ATE, but the increase in our study was modest and not statistically significant. However, patients who might be considered at highest risk of ATE, such as those who had suffered an ATE within 12 months, were excluded from the study protocol. The safety of bevacizumab in patients who have suffered a recent ATE is unknown, as they have also been excluded from most other studies using bevacizumab.
Data regarding the value of aspirin prophylaxis for ATE for patients on bevacizumab are conflicting. Scappaticci et al. reported that no conclusion could be drawn regarding its use owing to the small number of events per risk factor subgroup. There were, however, slightly more grade 3 and 4 bleeding events among aspirin users on bevacizumab (3.7%) than controls (1.8%). A separate pooled analysis of three trials of the safety of low-dose aspirin for primary prophylaxis for ATEs for patients on bevacizumab with chemotherapy for mCRC did not find any increased bleeding risk [15] . In our study, the rate of ATEs was moderately higher in patients on aspirin in conjunction with bevacizumab. However, these patients also had a higher incidence of prior ATEs as well as cardiac risk factors, making interpretation of any preventative effect associated with aspirin difficult.
The mechanism underlying the increased risk of ATE with bevacizumab is incompletely understood but likely relates to the role of VEGF in maintenance of the vascular endothelium. Inhibition of VEGF may result in endothelial disruption due to endothelial cell apoptosis, which is a postulated mechanism for both increased risk of haemorrhage and thrombosis due to exposure of the prothrombotic basement membrane and platelet activation [16] . These opposing risks make the prevention of ATE with antiplatelet agents and anticoagulation problematic and further data are needed regarding their safety and efficacy.
In conclusion, this study is unique in undertaking a detailed analysis of prospectively collected data in relation to vascular risk factors and ATEs in patients receiving bevacizumab. Overall, serious ATE will occur in approximately 1 in 27 patients treated with bevacizumab. Unlike other studies, neither age, prior history of ATEs nor presence of cardiac risk factors was significantly associated with a substantially increased risk of serious ATE in patients receiving bevacizumab. This information is vital in assessing the risk-benefit ratio associated with the use of this agent in older patients and patients with vascular comorbidities in routine clinical practice. 
